Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Quoin Pharmaceuticals Ltd.

NASDAQ: QNRX · Life Sciences · 7 alerts · CIK 1671502

Share price
$3.56Close, Nov 16
Market cap
$250M
Shares outstanding
70.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Quoin Pharmaceuticals Ltd. filings on SEC EDGAR ↗

5:05 PM ET 8-K
Other 8-K Filing

Quoin Pharmaceuticals Other 8-K Filing

Shareholders of Quoin Pharmaceuticals approved a proposal to amend beneficial ownership limitations for investors from previous private placements. The amendment allows investors to increase their ownership cap from 4.99% to up to 9.99% of outstanding ordinary shares upon written notice. This change applies to transactions consummated in October 2025 and August 2026 and aligns with both US and Israeli securities laws.

6:36 AM ET 8-K
Other 8-K Filing

Quoin Pharmaceuticals Other 8-K Filing

Quoin Pharmaceuticals announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its lead product candidate, QRX003, for the treatment of Peeling Skin Syndrome. This designation provides 10 years of market exclusivity in Europe upon potential marketing authorization and follows similar regulatory milestones in the US and Japan. The company remains on track to initiate the first-ever formal clinical study for Peeling Skin Syndrome before the end of 2026.

Counterparty
European Medicines Agency

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.